Colorectal Cancer

Phase II Trial Data Announced

Published in Cancer Weekly, June 20th, 2000

Xenova Group plc (XNVA; XEN), Slough, United Kingdom, announced trial data for a colorectal study, which is one of four open label Phase II efficacy studies currently being carried out in conjunction with the European Organisation for the Research and Treatment of Cancer (EORTC), on the topoisomerase I and II inhibitor, XR5000.

The purpose of these studies is to investigate the efficacy of XR5000 in a number of different tumor types in order to determine the best course of future clinical development.

Patients received XR5000 at a dose of 3,010 mg/m² in a 120-hour intravenous infusion every three weeks. Response was assessed following...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-06-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry